Publication:
Controversies in drug allergy: In vitro testing.

dc.contributor.authorMayorga, Cristobalina
dc.contributor.authorEbo, Didier G
dc.contributor.authorLang, David M
dc.contributor.authorPichler, Werner J
dc.contributor.authorSabato, Vito
dc.contributor.authorPark, Miguel A
dc.contributor.authorMakowska, Joanna
dc.contributor.authorAtanaskovic-Markovic, Marina
dc.contributor.authorBonadonna, Patrizia
dc.contributor.authorJares, Edgardo
dc.date.accessioned2023-01-25T10:26:48Z
dc.date.available2023-01-25T10:26:48Z
dc.date.issued2018-09-28
dc.description.abstractDespite their low frequency, drug hypersensitivity reactions (DHRs) can be serious and result in lifelong sequelae. The diagnosis is critical to avert future reactions and should identify the culprit drug or drugs and safe alternatives. However, making the diagnosis can be complex and challenging. Reliable in vitro tests can offer the potential to improve a diagnosis of DHR and influence medical decision making. Importantly, in vitro testing is frequently not performed as a test in isolation but rather as a component of a diagnostic algorithm along with additional tests. There are several in vitro approaches for the different endotypes of DHRs. However, only few are available for routine diagnosis, and many are restricted to research laboratories. In vitro tests exhibit varying sensitivity and specificity depending on the drug involved and the clinical phenotype. In vitro tests can complement skin tests, especially in patients with negative or equivocal skin test responses inconsistent with the clinical presentation and in severe reactions in which drug provocation tests are contraindicated. The main unmet need for many in vitro tests for the diagnosis of DHRs is validation in larger studies with standardized controls that could harmonize diagnostic management between the United States, European Union, and other regions of the world.
dc.description.versionSi
dc.identifier.citationMayorga C, Ebo DG, Lang DM, Pichler WJ, Sabato V, Park MA, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol. 2019 Jan;143(1):56-65
dc.identifier.doi10.1016/j.jaci.2018.09.022
dc.identifier.essn1097-6825
dc.identifier.pmid30573343
dc.identifier.unpaywallURLhttp://www.jacionline.org/article/S009167491831426X/pdf
dc.identifier.urihttp://hdl.handle.net/10668/13343
dc.issue.number1
dc.journal.titleThe Journal of allergy and clinical immunology
dc.journal.titleabbreviationJ Allergy Clin Immunol
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number56-65
dc.provenanceRealizada la curación de contenido 19/03/2025
dc.publisherElsevier
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S0091-6749(18)31426-X
dc.rights.accessRightsRestricted Access
dc.subjectDrug hypersensitivity
dc.subjectIgE
dc.subjectT-cells
dc.subjectAnaphylaxis
dc.subjectCytokine
dc.subjectDiagnostic
dc.subjectIn vitro tests
dc.subjectp-i concept
dc.subjectProliferation
dc.subjectSevere cutaneous reactions
dc.subject.decsPruebas Cutáneas
dc.subject.decsProteínas del Sistema Complemento
dc.subject.decsFenotipo
dc.subject.decsPredicción
dc.subject.decsHipersensibilidad a las Drogas
dc.subject.decsAlgoritmos
dc.subject.meshAnimals
dc.subject.meshClinical Decision-Making
dc.subject.meshDrug Hypersensitivity
dc.subject.meshHumans
dc.subject.meshSkin Tests
dc.titleControversies in drug allergy: In vitro testing.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number143
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format